TRACON Pharmaceuticals, Inc.(NASDAQ : TCON)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.34%||178.12||0.7%||$1344.93m|
|MRK||Merck & Co., Inc.||0.55%||91.67||0.7%||$1174.23m|
|LLY||Eli Lilly & Co.||-0.91%||321.27||1.1%||$1036.13m|
|BMY||Bristol-Myers Squibb Co.||-1.00%||76.23||1.0%||$997.78m|
|TPTX||Turning Point Therapeutics, Inc.||-0.12%||75.16||0.0%||$287.74m|
|HZNP||Horizon Therapeutics Plc||1.04%||80.59||5.4%||$163.49m|
|MRTX||Mirati Therapeutics, Inc.||2.96%||69.12||1.6%||$151.06m|
|NVO||Novo Nordisk A/S||-0.54%||110.83||0.1%||$142.45m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||-0.17%||145.47||0.0%||$142.09m|
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.